Novartis announces collaboration with Molecular Partners to develop two DARPin therapies designed for potential use against COVID-19 - Seite 5
About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments
in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis medicines reach nearly 800
million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out
more at
https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com
# # #
Novartis Media Relations
E-mail: media.relations@novartis.com
Name Antonio Ligi Novartis External Communications +41 79 723 3681 (mobile) antonio.ligi@novartis.com Name Eric Althofff Novartis US External Communications +1 646 438 4335 (mobile) eric.althoff@novartis.com |
Name Katrina Lucking +41 79 484 7625 (mobile) katrina.lucking@novartis.com |
Lesen Sie auch
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
Central | North America | ||
Samir Shah | +41 61 324 7944 | Sloan Simpson | +1 862 778 5052 |
Thomas Hungerbuehler Isabella Zinck |
+41 61 324 8425 +41 61 324 7188 |
||